| Closed |
S0420 |
Recurrent or Metastatic Head and Neck Cancer |
10/1/2004 |
|
100% |
|
Published
|
| Closed |
S0618 |
Recurrent or Metastatic Squamous Cell |
5/1/2006 |
1/1/2008 |
95% |
|
Published
|
| Closed |
S9902 |
Recurrent, Refractory or Metastatic |
11/15/1999 |
1/1/2001 |
97% |
|
Published
|
| Closed |
S9807 |
Recurrent, Refractory or Metastic |
9/1/1998 |
2/15/2004 |
|
|
|
| Closed |
S0308 |
Reduction of Skeletal Events in Advanced Breast Cancer |
5/15/2006 |
6/8/2006 |
0% |
|
|
| Closed |
S9922 |
Refractory Myeloma |
4/15/2000 |
11/1/2001 |
6% |
|
|
| Closed |
SWOG-8461 |
Registration and Evaluation of Patients Aged 55 and Over with Unfavorable Histology NHL |
6/1/1984 |
3/20/1986 |
|
|
Published
|
| Closed |
S0010 |
Relapsed/Refractory Non T-Cell ALL |
7/15/2000 |
3/15/2004 |
48% |
|
|
| Closed |
SWOG-7315/16 |
Remission Induction for Adult Acute Leukemia with Ten-day OAP Remission Maintenance with OAP vs OAP plus BCG |
7/6/1973 |
1/1/1977 |
|
|
Published
|
| Closed |
SWOG-9230 |
Renal |
6/1/1993 |
5/1/1995 |
100% |
|
Published
|
| Closed |
SWOG-8949 |
Renal |
3/1/1991 |
10/1/1998 |
100% |
|
Published
|
| Closed |
SWOG-9451 |
Resectable Head and Neck |
4/12/1996 |
12/1/2001 |
87% |
|
Published
|
| Closed |
SWOG-7823/24/25/26 |
ROAP-AdOAP in Acute Adult Leukemia |
8/4/1978 |
9/10/1982 |
|
|
Published
|
| Closed |
S1513 |
RPh II of 2nd Line FOLFIRI w/ or w/o Veliparib (ABT888) in met panc cancer |
9/1/2016 |
|
86% |
|
|
| Closed |
S1613 |
RPh II Pertuzumab+Trastuzumab vs CETIRI mCRC w/HER2 amp |
10/9/2017 |
12/31/2021 |
42% |
|
|
| Closed |
S1304 |
RPII Dex + High or Low Dose Carfilzomib for R/R MM |
10/18/2013 |
5/15/2016 |
100% |
|
|
| Closed |
SWOG-7404 |
RT + CCNU and Procarbazine vs. RT + CCNU Followed by the Sequential Use of Procarbazine after Relapse in Patients with Malignant Gliomas |
6/25/1974 |
3/7/1977 |
|
|
|
| Closed |
SWOG-7703 |
RT in Combination with BCNU, Dimethyl Triazeno Imidazole Carboxamide (DTIC) or Procargazine in Patients with Malignant Gliomas of the Brain |
3/7/1977 |
7/28/1981 |
|
|
Published
|
| Open |
S2200 |
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2 |
9/19/2022 |
|
18% |
|
|
| Closed |
S2007 |
Sacituzumab Govitecan for HER2-Neg Breast Cancer and Brain Metastases |
12/15/2020 |
|
64% |
|
|
